InvestorsHub Logo
Followers 31
Posts 2649
Boards Moderated 0
Alias Born 10/28/2013

Re: MolBiol post# 7351

Thursday, 03/27/2014 4:39:17 PM

Thursday, March 27, 2014 4:39:17 PM

Post# of 702610
MolBio: I had not been counting on Direct killing all tumors at other sites than the injected tumor, because that sounds so difficult. I never understood why there would be that expectation.

Rather, if metastasis killing is not expected for L, then why for Direct?

But didn't L work to kill metastasis in the Ovarian trial?

I know there is new technology in Direct, but the technology I have heard about does not sound like something that would help with the satellite (easier to spell) tumors. But maybe it doesn't have to be an improvement over L in that regard.

A point I am working toward is that without basis other than common sense, it would seem that tiny metastasis would be more vulnerable to attack by the immune system than larger tumors. So that if the larger tumors all got injected, then just like chemo works against the small metastasis, so might DCVax of either variety, L or Direct.

And Linda Powers did make it a point to say in the previous talk that virtually all non-operable tumors can be reached by a guided needle. Of course, she kind of had to say that. But... I buy it. And as much of a pain as that process might be, it is infinitely superior to radiation... or so it would seem from my semi-layman point of view.

So you inject the larger tumors. Then you inject any metastasis of significant size that squeak through. And the countless tiny metastasis that spring up get killed by the immune response. You never see them.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News